Search Results

Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”) held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”).

Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis and in a preclinical model on colon cancer, will be presented at Digestive Disease Week as part of scientific exchange, taking place May 18-21, 2024, in Washington D.C., U.S.